Recurrences and Deaths Prevented by Atezolizumab Translate to Lower Cost of Care
Adjuvant atezolizumab can prevent recurrence and death, thereby reducing costs, in patients with early non-small cell lung cancer, a study suggests.
Adjuvant atezolizumab can prevent recurrence and death, thereby reducing costs, in patients with early non-small cell lung cancer, a study suggests.
Recommendations for venous thromboembolism prophylaxis in patients with cancer were discussed in an oral session at JADPRO Live 2022.
Researchers sought to identify the challenges that patients and healthcare providers experience with understanding and using biomarker test results.
Patients with mHSPC who receive enzalutamide plus ADT are 4 times more likely to achieve undetectable PSA levels than patients who receive ADT alone, according to an analysis of data from the ARCHES trial.
African-American women who survive breast cancer do not get adequate resources to support their mental and emotional health, a small study suggests.
Patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis have an increased risk of venous thromboembolism, a study suggests.
Intermittent fasting appears safe as an adjunct to chemotherapy, but it is unclear whether this diet can improve cancer outcomes.
Real-world data support first-line palbociclib plus an aromatase inhibitor as standard care for HR+, HER2- metastatic breast cancer, according to researchers.
Results of an ACCC study revealed advanced practitioners’ greatest challenges when treating cancer patients with combination IV/oral therapies.
A poster presentation at JADPRO Live 2022 described the benefits of using simulation training in combination with didactic educational sessions to improve knowledge and confidence for bone marrow transplant APPs.